当前位置: 首页 > 详情页

Efficacy and safety of FIREHAWK (R) abluminal groove filled biodegradable polymer sirolimus-eluting stents for the treatment of long coronary lesions: nine-month angiographic and one-year clinical results from TARGET I trial long cohort

文献详情

资源类型:

收录情况: ◇ SCIE ◇ 统计源期刊 ◇ CSCD-C ◇ 中华系列

机构: [1]Chinese Acad Med Sci, Dept Cardiol, Fu Wai Hosp, Natl Ctr Cardiovasc Dis China, Beijing 100037, Peoples R China; [2]Chinese Acad Med Sci, Div Biometr, Fu Wai Hosp, Natl Ctr Cardiovasc Dis China, Beijing 100037, Peoples R China; [3]Peiking Union Med Coll, Beijing 100037, Peoples R China; [4]Shanghai Jiao Tong Univ, Sch Med, Affiliated Ruijin Hosp, Dept Cardiol, Shanghai 200025, Peoples R China; [5]Fourth Mil Med Univ, Affiliated Xijing Hosp, Dept Cardiol, Xian 710032, Shaanxi, Peoples R China; [6]Liaoning Prov Peoples Hosp, Dept Cardiol, Shenyang 110016, Liaoning, Peoples R China; [7]Capital Med Univ, Affiliated An Zhen Hosp, Dept Cardiol, Beijing 100029, Peoples R China; [8]Shenyang Northern Hosp, Dept Cardiol, Shenyang 110015, Liaoning, Peoples R China; [9]Yale New Haven Med Ctr, New Haven, CT 06504 USA; [10]Peking Univ, Hosp 1, Dept Cardiol, Beijing 100034, Peoples R China; [11]Columbia Univ, Med Ctr, New York, NY USA; [12]Cardiovasc Res Fdn, New York, NY USA
出处:
ISSN:

关键词: sirolimus drug-eluting stents biodegradable coronary artery disease

摘要:
Background Previous studies indicated that long coronary lesions are one of the key predictors of drug-eluting stent (DES) failure. The purpose of this study was to evaluate the efficacy and the safety of the long length FIREHAWK (R) stent in long coronary artery disease. Methods The long cohort of TARGET I was a prospective, multicenter, single arm trial. It was planned to enroll 50 patients undergoing percutaneous coronary intervention (PCI) for the treatment of de novo long lesions in a native coronary artery. The major inclusion criteria of the trial was that patients were intended to undergo the treatment of a long target lesion(s) with diameter stenosis >= 70% and reference vessel diameter 2.5 mm to 4.0 mm by visual estimate, that needed to be covered by at least one 33 mm or 38 mm stent or multiple long stents overlapped. The angiographic follow-up was planned at 9-month and the clinical follow-up will be up to 5 years. The primary end point was in-stent late lumen loss at 9-month. Results Fifty patients (mean age (57.6 +/- 10.2) years) with 59 de novo long lesions (reference vessel diameter (2.85 +/- 0.44) mm, lesion length (35.2 +/- 9.4) mm, and stent length (41.8 +/- 11.3) mm) were enrolled. The angiographic follow-up rate was 92% at 9-month. The in-stent late loss was (0.16 +/- 0.16) mm. Proximal edge, distal edge and in-segment late loss (mm) were 0.21 +/- 0.35, 0.03 +/- 0.33, and 0.07 +/- 0.26, respectively. No in-segment binary restenosis was observed. At 1-year no death, Q wave myocardial infarction (MI), or stent thrombosis occurred. Non-Q-wave MI occurred in two patients (4%) due to procedural complications. Conclusions Treatment of long coronary lesions with the FIREHAWK (R) stent is able to produce similar results as observed in the FIREHAWK (R) FIM clinical trial. Based on this result, we are confident in the treatment prospect of the FIREHAWK (R) for long coronary lesions.

语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2012]版:
大类 | 4 区 医学
小类 | 4 区 医学:内科
最新[2023]版:
大类 | 3 区 医学
小类 | 3 区 医学:内科
JCR分区:
出版当年[2011]版:
Q3 MEDICINE, GENERAL & INTERNAL
最新[2023]版:
Q1 MEDICINE, GENERAL & INTERNAL

影响因子: 最新[2023版] 最新五年平均 出版当年[2011版] 出版当年五年平均 出版前一年[2010版] 出版后一年[2012版]

第一作者:
第一作者机构: [1]Chinese Acad Med Sci, Dept Cardiol, Fu Wai Hosp, Natl Ctr Cardiovasc Dis China, Beijing 100037, Peoples R China;
通讯作者:
通讯机构: [1]Chinese Acad Med Sci, Dept Cardiol, Fu Wai Hosp, Natl Ctr Cardiovasc Dis China, Beijing 100037, Peoples R China; [3]Peiking Union Med Coll, Beijing 100037, Peoples R China;
推荐引用方式(GB/T 7714):
APA:
MLA:

相关文献

[1]Biodegradable Polymer-Based Sirolimus-Eluting Stents with Differing Elution and Absorption Kinetics the PANDA III Trial [2]Novel completed biodegradable polymer sirolimus-eluting stent versus durable polymer sirolimus-eluting stent in de novo lesions: nine-month angiographic and three-year clinical outcomes of HOPE trial [3]Five-Year Outcomes of Biodegradable Polymer Drug-Eluting Stents Versus Second-Generation Durable Polymer Drug-Eluting Stents: a Meta-Analysis of Randomized Controlled Trials [4]Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent for the treatment of de novo coronary lesions: Final five-year results of the patient-level pooled analysis from the TARGET I and TARGET II trials [5]非顺应球囊后扩张对置入药物洗脱支架预后的影响 [6]Impact of chronic kidney disease on patients with unprotected left main coronary artery disease treated with coronary artery bypass grafting or drug-eluting stents [7]Very Long-term Outcomes and Predictors of Percutaneous Coronary Intervention with Drug-eluting Stents Versus Coronary Artery Bypass Grafting for Patients with Unprotected Left Main Coronary Artery Disease [8]Very Long-term Outcomes of Percutaneous Coronary Intervention with Drug-eluting Stents versus Coronary Artery Bypass Grafting for Patients with Unprotected Left Main Coronary Artery Disease [9]Biodegradable polymer drug-eluting stents versus second-generation drug-eluting stents in patients with and without diabetes mellitus: a single-center study [10]Infuence of diabetes mellitus on long-term outcomes of patients with unprotected left main coronary artery disease treated with either drug-eluting stents or coronary artery bypass grafting

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院